Join the Cassipa group to help and get support from people like you.
Cassipa News
Opioids Can Be Continued in Cancer Patients With Nonmedical Stimulant Use
MONDAY, Sept. 11, 2023 – For patients with cancer-related pain and nonmedical stimulant use, opioids should be continued, monitoring increased, and tapering avoided, according to a study published...
Just 1 in 5 Americans Struggling With Opioid Misuse Gets Meds That Can Help
MONDAY, Aug. 7, 2023 – The U.S. opioid abuse epidemic wages on, and overdose deaths continue to rise, yet just 1 in 5 people receives potentially lifesaving medication such as methadone,...
FDA Medwatch Alert: FDA Warns About Dental Problems with Buprenorphine Medicines Dissolved in the Mouth to Treat Opioid Use Disorder and Pain
What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that dental problems have been reported with medicines containing buprenorphine that are dissolved in the...
FDA Medwatch Alert: Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder - FDA Recommends Health Care Professionals Discuss Naloxone with All Patients when Prescribing
ISSUE: FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information....
FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 – The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid...
Ask a question
To post your own question to this support group, sign in or create an account.